Regulatory Affairs Editorial

  1. What's The Risk Of Letting Researchers Use LLMs? 5/21/2025

    Who should be using AI and how? Sage Therapeutics' Jake Alme explores AI use in clinical research, examining its use shifting toward more complex applications and discussing the risk of using it in the public domain.

  2. Celebrating Clinical Trials Day, Part 2: Trial Optimization In Action 5/20/2025

    Celebrate Clinical Trials Day 2025 with these industry experts as they share experiences and advice related to trial design, regulatory and compliance, and outsourcing challenges.

  3. 3 Strategies For A Successful Journey Toward Cell And Gene Therapy Commercialization 5/13/2025

    CTMC's Amy Hay provides 3 recommendations for teams developing cell and gene therapies, from clinical research through commercialization.

  4. AI In Medical Devices: Meeting The Regulatory Challenge Around The World, Part 2 5/13/2025

    This article focuses on the common regulatory threads that connect different regions and the global standards and principles being developed to bring consistency, safety, and trust to AI innovation in medical devices.

  5. The Potential Impact Of U.S. Tariffs On The Biotech Sector: Manufacturing, Funding, And Clinical Trials 5/12/2025

    Syner-G Biopharma Group's Raymond Forslund, Ph.D., MBA explores how U.S. tariffs might affect biotech manufacturing, funding, and clinical research.

  6. U.K. Has Strong Plan To Reform Clinical Trials 5/8/2025

    The U.K.’s 2025 clinical trial reforms aim to boost research efficiency, inclusivity, and global competitiveness by streamlining approvals, enhancing patient involvement, and addressing structural, demographic, and therapeutic gaps in trial activity.

  7. How Close Is The First FDA-Approved Full-Spectrum Botanical Drug For Autism? 5/6/2025

    AJNA BioSciences CEO Joel Stanley details his transition from helping to build one of the largest CBD companies to developing what he hopes will become an FDA-approved botanical drug to treat the symptoms of autism.

  8. EMA Issues Draft Reflection Paper On Accelerating Biosimilar Approval 5/5/2025

    In April, the European Medicines Agency issued a draft of a new guidance document titled Reflection paper on a tailored clinical approach in biosimilar development. The public consultation runs until Sept. 30, 2025.

  9. DEI Was Never the Problem, The Way Pharma Did It Was 5/5/2025

    Consultant Denise Bronner details pharma's strategic rollback of DEI initiatives, roles, and even departments and explains why well-meaning but misguided intentions enabled their demise.

  10. AI In Medical Devices: Meeting The Regulatory Challenge Around The World, Part 1 5/1/2025

    This article explores the global regulatory landscape, examining how leading authorities in the U.S., EU, U.K., Canada, China, Brazil, Australia, and South Korea are approaching AI in medical devices.